Comparing Treace Medical Concepts (NASDAQ:TMCI) and Inovio Pharmaceuticals (NASDAQ:INO)

Treace Medical Concepts (NASDAQ:TMCIGet Rating) and Inovio Pharmaceuticals (NASDAQ:INOGet Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends.

Institutional and Insider Ownership

34.8% of Treace Medical Concepts shares are held by institutional investors. Comparatively, 43.3% of Inovio Pharmaceuticals shares are held by institutional investors. 41.9% of Treace Medical Concepts shares are held by insiders. Comparatively, 3.3% of Inovio Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.


This table compares Treace Medical Concepts and Inovio Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Treace Medical Concepts -25.92% -28.57% -19.15%
Inovio Pharmaceuticals -20,479.29% -76.48% -63.47%

Risk and Volatility

Treace Medical Concepts has a beta of -1.09, meaning that its share price is 209% less volatile than the S&P 500. Comparatively, Inovio Pharmaceuticals has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and target prices for Treace Medical Concepts and Inovio Pharmaceuticals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Treace Medical Concepts 0 0 4 0 3.00
Inovio Pharmaceuticals 0 5 0 0 2.00

Treace Medical Concepts currently has a consensus price target of $28.50, indicating a potential upside of 83.99%. Inovio Pharmaceuticals has a consensus price target of $11.80, indicating a potential upside of 487.06%. Given Inovio Pharmaceuticals’ higher probable upside, analysts plainly believe Inovio Pharmaceuticals is more favorable than Treace Medical Concepts.

Valuation & Earnings

This table compares Treace Medical Concepts and Inovio Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Treace Medical Concepts $94.42 million 9.07 -$20.55 million ($0.50) -30.98
Inovio Pharmaceuticals $1.77 million 260.10 -$303.66 million ($1.54) -1.31

Treace Medical Concepts has higher revenue and earnings than Inovio Pharmaceuticals. Treace Medical Concepts is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.


Treace Medical Concepts beats Inovio Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Treace Medical Concepts Company Profile (Get Rating)

Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of medical devices for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, and autograft bone harvesting, as well as for MTP fusion. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra Beach, Florida.

Inovio Pharmaceuticals Company Profile (Get Rating)

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

Receive News & Ratings for Treace Medical Concepts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Treace Medical Concepts and related companies with's FREE daily email newsletter.